


Reaction of Diazomethane with Clerocidin. Preparation of New Clerodane Diterpenoid Derivatives

J.P. Jacquet*, D. Bouzard, and P. Remuzon


Bristol-Myers Squibb Pharmaceutical Research Institute, BP 62,
77422 Marne-la-Vallée Cedex 2, FRANCE

Abstract: Reaction of 1 with diazomethane in MeOH gave the ketone 2 as well as the diepoxide 4. The alcohol 3, obtained by hydrolysis of 2 was acetylated and oxidized to give 6.


Clerocidin, a natural clerodane diterpenoid was isolated from *Oidiodendron truncatum* as a methanol adduct^{1,2}. This molecule, which showed antibacterial activity³, was found to be a potent DNA topoisomerase II inhibitor^{4,5}. In order to design new DNA gyrase inhibitors, we were interested in an "open form" of the oxygenated part of clerocidin.



In this paper we describe the reaction of 1 with diazomethane and the acetylation and oxidation of the acetylated intermediate 3.




Reaction of diazomethane with **1** in MeOH at $-5\text{ }^\circ\text{C}$ gave a mixture of **2**⁶ (43%), **3**⁷ (< 5 %) and **4**⁸ (15 %), which were easily separated by chromatography. These reactions involved two mechanisms for the loss of dinitrogen following the attack of diazomethane on the ketone



Scheme 2

function of the oxygenated ring (Scheme 2). The first mechanism (①) provided the diepoxide **4** by a classical reaction⁹. The second (②) was "non-classical", beginning with a shift of the anomeric hydrogen, followed by the opening of the sugar-like moiety, furnishing the ketone **2**.

Treatment of **2** with one equivalent of 0.1N NaOH in EtOH gave the alcohol **3** in quantitative yield. Acetylation of **3** with Ac₂O/pyridine at 0 °C provided the pure crystalline derivative **5**¹⁰ in 85 % yield.



Oxidation (SeO₂, aq. dioxane, reflux 48 h)¹¹ of the acetyl derivative **5** furnished in 60 % yield after chromatography, the corresponding aldehyde **6**¹², isolated as hydrate.

None of these semi-synthetic clerodane derivatives showed better biological activity than clerocidin. Nevertheless derivative **4** displayed weak antibacterial properties.

Acknowledgements:

We thank Dr. S. Taylor and N. Soundararajan from BMS Pharmaceutical Development for providing us clerocidin methanol adduct and the BMS-France Analytical Department Laboratory for spectral determinations and microanalyses.

References and Notes

1. Andersen, N. R.; Rasmussen, P. R. *Tetrahedron Lett.* **1984**, *25*, 465.
2. Andersen, N. R.; Rasmussen, P. R.; Falshaw, C. P.; King T. J. *Tetrahedron Lett.* **1984**, *25*, 469.
3. Andersen, N. R.; Lorck, H. O. B.; Rasmussen, P. R. *J. Antibiotics* **1983**, *36*, 753.
4. Kawada, S-z.; Yamashita, Y.; Fujii, N.; Nakano, H. *Cancer Res.* **1991**, *51*, 2922.
5. Nakano, H. *Gan To Kagaku Ryoho*, **1991**, *18*, 1550.
6. Compound **2**: white crystals, mp. 98 °C, ^1H NMR (CDCl_3) δ : 0.93 (d, $J = 7.0$ Hz, 3H, **Me-11**); 1.00 (s, 3H, **Me-12**); 1.17 (s, 3H, **Me-10**); 1.20 -1.93 (m, 9H, **CH₂-4**, **CH-6**, **CH₂-7**, **CH-8**, **CH-8a**, **CH₂-13**); 2.01 (s, 3H, **COCH₃-20**); 2.27-2.40 (m, 3H, **CH₂-3**, **CH-8**); 2.97 (d, $J_{\text{AB}} = 5.0$ Hz, 1H, **CH₂ epoxide**); 3.00 (d, $J_{\text{AB}} = 5.0$ Hz, 1H, **CH₂ epoxide**); 5.33 (m, 1H, **H-14**); 6.48 (m, 1H, **H-2**); 7.96 (s, 1H, **OCHO-17**); 9.24 (s, 1H, **CHO-9**). ^{13}C NMR, EA, IR and MS spectral data were in accord with the structure. $[\alpha]_{\text{D}}^{25} + 49^\circ$ (c 0.25, CHCl_3).
7. Compound **3**: white crystals, mp. 110 °C. ^1H , ^{13}C NMR, EA, and IR spectral data were in accord with the structure. $[\alpha]_{\text{D}}^{25} + 93^\circ$ (c 0.1, CHCl_3).
8. Compound **4**: white crystals, mp 135-140 °C. ^1H NMR (CDCl_3): mixture of 2 anomers. EA, IR and ^{13}C spectral data were in accord with the structure. $[\alpha]_{\text{D}}^{25} + 97^\circ$ (c 0.125, CHCl_3).
9. Black, T. H. *Aldrichimica Acta* **1983**, *16*, 3.
10. Compound **5**: purified by flash chromatography, ^1H NMR (CDCl_3) δ : 0.99 (d, $J = 7.0$ Hz, 3H, **Me-11**); 1.06 (s, 3H, **Me-12**); 1.23 (s, 3H, **Me-10**); 1.26 -1.95 (m, 9H, **CH₂-4**, **CH-6**, **CH₂-7**, **CH-8**, **CH-8a**, **CH₂-13**); 2.04 (s, 3H, **COCH₃-20**); 2.06 (s, 3H, **OCOCH₃-17**); 2.36-2.43 (m, 3H, **CH₂-3**, **CH-8**); 2.98 (d, $J_{\text{AB}} = 5.0$ Hz, 1H, **CH₂ epoxide**); 3.01 (d, $J_{\text{AB}} = 5.0$ Hz, 1H, **CH₂ epoxide**) 5.29 (m, 1H, **H-14**); 6.54 (m, 1H, **H-2**); 9.29 (s, 1H, **CHO-9**).
11. Bailey, M.; Marko, I.; Ollis, D.; Rasmussen, P.R. *Tetrahedron Lett.* **1990**, *31*, 4509.
12. Compound **6**: purified by chromatography, amorphous powder (mixture of isomers). ^1H , ^{13}C NMR, EA and IR spectral data were consistent with the proposed structure.

(Received in France 24 September 1992)